Advances on the mechanism and dignosis of lacrimal gland lesions in thyroid-associated ophthalmopathy

doi:10.3877/cma.j.issn.2095-2007.2020.01.010

Abstract

Abstract:

Thyroid associated ophthalmopathy (TAO) is an organ specific autoimmune disease associated with autoimmune thyroid disease. TAO changed pathologically orbital fat, extraocular muscles, and lacrimal glands to some extent. The majority of patients with TAO had dry eye symptoms, such as decreased vision, photophobia, tearing, grittiness in the eye, etc. Dry eye syndrome caused by ocular surface injury was the most common cause of ocular discomfort in TAO patients. Studies have shown that lacrimal gland may be directly involved in the pathogenesis of ocular surface injury in TAO patients. The research progress of TAO related lacrimal gland lesions from the aspects of ocular surface changes, mechanism of lacrimal gland lesions, and lacrimal gland imaging were reviewed , which could be of benifit to provide reference for further study and clinical treatment.

Key words: Thyroid associated ophthalmopathy, Lacrimal gland, Function, Imaging

Xingyu Ma, Zhaoxia Zhang, Bin Sun. Advances on the mechanism and dignosis of lacrimal gland lesions in thyroid-associated ophthalmopathy[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2020, 10(01): 58-62.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2020.01.010

https://zhykyxzz.cma-cmc.com.cn/EN/Y2020/V10/I01/58

Figures/Tables 1

References 54

[1]	Bahn RS. Graves′ ophthalmopathy[J]. N Engl J Med, 2010, 362(8): 726-738.
[2]	宋国祥. 眼眶病学[M]. 北京：人民卫生出版社，2010.
[3]	Maheshwari R, Weis E. Thyroid associated orbitopathy[J]. Indian J Ophthalmol, 2012, 60(2): 87-93.
[4]	Kashkouli MB, Alemzadeh SA, Aghaei H, et al. Subjective vs objective dry eye disease in patients with moderate-severe thyroid eye disease[J]. Ocul Surf, 2018, 16(4): 458-462.
[5]	Achtsidis V, Tentolouris N, Theodoropoulou S, et al. Dry eye in Graves′ ophthalmopathy: correlation with corneal hypoesthesia[J]. Eur J Ophthalmol, 2013, 23(4): 473-479.
[6]	Selter JH, Gire AI, Sikder S. The relationship between Graves′ ophthalmopathy and dry eye syndrome[J]. Clin Ophthalmol, 2015, 9: 57-62.
[7]	Iskeleli G, Karakoc Y, Abdula A. Tear film osmolarity in patients with thyroid ophthalmopathy[J]. Jpn J Ophthalmol, 2008, 52(4): 323-326.
[8]	Bruscolini A, Abbouda A, Locuratolo N, et al. Dry eye syndrome in non-exophthalmic Graves′ disease[J]. Semin Ophthalmol, 2015, 30(5/6): 372-376.
[9]	Aggarwal S, Galor A. What′s new in dry eye disease diagnosis? [J]. F1000Research, 2018, 7: 1952.
[10]	Brito-Zerón P, Baldini C, Bootsma H, et al. Sjögren syndrome[J]. Nat Rev Disease primers, 2016, 2(15): 16047.
[11]	Rosenbaum JT, Choi D, Harrington CA, et al. Gene expression profiling and heterogeneity of nonspecific orbital inflammation affecting the lacrimal gland[J]. JAMA Ophthalmol, 2017, 135(11): 1156-1162.
[12]	Łacheta D, Miskiewicz P, Głuszko A, et al. Immunological aspects of Graves′ ophthalmopathy[J]. Biomed Res Int, 2019, 2019：7453260.
[13]	Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor[J]. J Clin Endocrinol Metab, 2004, 89(10): 5076-5080.
[14]	Marinò M, Rotondo DG, Ionni I, et al. Serum antibodies against the insulin-like growth factor-1 receptor in Graves′ disease and Graves′ orbitopathy[J]. J Endocrinol Invest, 2019, 42(4): 471-480.
[15]	Gerding MN, van Meer JW, Broenink M, et al. Association of thyrotrophin receptor antibodies with the clinical features of Graves′ ophthalmopathy[J]. Clin Endocrinol, 2000, 52(3): 267-271.
[16]	Harris MA, Realini T, Hogg JP, et al. CT dimensions of the lacrimal gland in Graves orbitopathy[J]. Ophthal Plast Reconstr Surg, 2012, 28(1): 69-72.
[17]	王毅，孙丰源. 细胞间黏附分子-1在甲状腺相关眼病泪腺组织中的表达及意义[J]. 眼科研究，2003, 21 (2): 153-155.
[18]	Park J, Baek S. Dry eye syndrome in thyroid eye disease patients: The role of increased incomplete blinking and Meibomian gland loss[J]. Acta Ophthalmol, 2019, 97(5): e800-e806.
[19]	Rocha EM, Mantelli F, Nominato LF, et al. Hormones and dry eye syndrome: an update on what we do and don′t know[J]. Curr Opin Ophthalmol, 2013, 24(4): 348-355.
[20]	Zhou L, Zhao SZ, Koh SK, et al. In-depth analysis of the human tear proteome[J]. J Proteomics, 2012, 75(13): 3877-3885.
[21]	De Souza GA, De Godoy LM, Mann M. Identification of 491 proteins in the tear fluid proteome reveals a large number of proteases and protease inhibitors[J]. Genome Biol, 2006, 7(8): R72.
[22]	程妍. 甲状腺相关眼病患者血清及泪液TPOAb、TRAb的检测及相关性分析[D]. 长春：吉林大学，2014.
[23]	Aass C, Norheim I, Eriksen EF, et al. Comparative proteomic analysis of tear fluid in Graves′ disease with and without orbitopathy[J]. Clin Endocrinol (Oxf), 2016, 85(5): 805-812.
[24]	Huang D, Luo Q, Yang H, et al. Changes of lacrimal gland and tear inflammatory cytokines in thyroid-associated ophthalmopathy[J]. Invest Ophthalmol Vis Sci, 2014, 55(8): 4935-4943.
[25]	Khalil HA, De Keizer RJW, Bodelier VMW, et al. Secretory IgA and lysozyme in tears of patients with Graves′ ophthalmopathy[J]. Doc Ophthalmol, 1989, 72(3): 329-334.
[26]	Khalil HA, Keizer RJW, Kijlstra A. Analysis of tear proteins in Graves′ ophthalmopathy by high performance liquid chromatography[J]. Am J Ophthalmol, 1988, 106(2): 186-190.
[27]	Baker GR, Morton M, Rajapaska RS, et al. Altered tear composition in smokers and patients with graves ophthalmopathy[J]. Arch Ophthalmol, 2006, 124(10): 1451-1456.
[28]	Aass C, Norheim I, Eriksen EF, et al. Establishment of a tear protein biomarker panel differentiating between Graves′ disease with or without orbitopathy[J]. PLoS One, 2017, 12(4): e0175274.
[29]	Chng CL, Seah LL, Yang M, et al. Tear proteins calcium binding protein A4 and prolactin induced protein are potential biomarkers for thyroid eye disease[J]. Sci Rep, 2018, 8(1): 16936.
[30]	Kishazi E, Dor M, Eperon S, et al. Differential profiling of lacrimal cytokines in patients suffering from thyroid-associated orbitopathy[J]. Sci Rep, 2018, 8(1): 10792.
[31]	Huang D, Xu N, Song Y, et al. Inflammatory cytokine profiles in the tears of thyroid-associated ophthalmopathy[J]. Graefe′s Arch Clin Exp Ophthalmol, 2012, 250(4): 619-25.
[32]	Sadoul JL. L′ophtalmopathie thyroïdienne à l'heure de l′European Group on Graves orbitopathy [J]. Presse Med, 2011, 40(12): 1163-1173.
[33]	Bartalena L, Pinchera A, Marcocci C. Management of Graves′ ophthalmopathy: reality and perspectives[J]. Endocr Rev, 2000, 21(2): 168-199.
[34]	Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European thyroid association/European group on Graves′ Orbitopathy guidelines for the Management of Graves′ Orbitopathy[J]. Eur Thyroid J, 2016, 5(1): 9-26.
[35]	Mourits MPH, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves′ ophthalmopathy: a novel approach[J]. Br J Ophthalmol, 1989, 73(8): 639-644.
[36]	Ferreira TA, Saraiva P, Genders SW, et al. CT and MR imaging of orbital inflammation[J]. Neuroradiology, 2018, 60(12): 1253-1266.
[37]	Byun JS, Moon NJ, Lee JK. Quantitative analysis of orbital soft tissues on computed tomography to assess the activity of thyroid-associated orbitopathy[J]. Graefe′s Arch Clin Exp Ophthalmol, 2017, 255(2): 413-420.
[38]	Regensburg NI, Kok PH, Zonneveld FW, et al. A new and validated CT-based method for the calculation of orbital soft tissue volumes[J]. Invest Ophthalmol Vis Sci, 2008, 49(5): 1758-1762.
[39]	Huh HD, Kim JH, Kim SJ, et al. The change of lacrimal gland volume in Korean patients with thyroid-associated ophthalmopathy[J]. Korean J Ophthalmol, 2016, 30(5): 319-325.
[40]	Conneely MF, Hacein-Bey L, Jay WM. Magnetic resonance imaging of the orbit[J]. Semin Ophthalmol, 2008, 23(3): 179-189.
[41]	Kahaly GJ. Recent developments in Graves′ ophthalmopathy imaging[J]. J Endocrinol Invest, 2004, 27(3): 254-258.
[42]	韩雪立，吴恩余. Graves眼病的CT和MRI影像学分析[J]. 白求恩医科大学学报，2001, 17(5): 540-542.
[43]	Hu H, Xu XQ, Wu FY, et al. Diagnosis and stage of Graves′ ophthalmopathy: Efficacy of quantitative measurements of the lacrimal gland based on 3-T magnetic resonance imaging[J]. Exp Ther Med, 2016, 12(2): 725-729.
[44]	Gagliardo C, Radellini S, Bubella RM, et al. Lacrimal gland herniation in Graves ophthalmopathy: a simple and useful MRI biomarker of disease activity[J]. Eur Radiol, 2020, 30(1): 2138-2141.
[45]	沈洁，戈荧，范艳飞，等. 泪腺及眼外肌MRI-T2值在甲状腺相关眼病活动期评判中的价值[C]. 杭州：中华医学会第十次全国内分泌学学术会议，2011.
[46]	Krassas GE. Somatostatin analogues in the treatment of thyroid eye disease[J]. Thyroid, 1998, 8(5): 443-445.
[47]	孙斌. 生长抑素类似物眼眶显像在甲状腺相关性眼病诊疗中的应用[J]. 眼科，2016, 25(6): 361-364.
[48]	孙斌，吕兆琴，李险峰. 甲状腺相关眼病眶部⁹⁹Tc^m-生长抑素类似物受体显像的应用价值[J]. 中国实用眼科杂志，2008, 26(1): 90-92.
[49]	Moncayo R, Baldissera I, Decristoforo C, et al. Evaluation of immunological mechanisms mediating thyroid-associated ophthalmopathy by radionuclide imaging using the somatostatin analog ¹¹¹In-octreotide[J]. Thyroid, 1997, 7(1): 21-29.
[50]	Sweeney RA, Bale RJ, Moncayo R, et al. Multimodality cranial image fusion using external markers applied via a vacuum mouthpiece and a case report[J]. Strahlenther Onkol, 2003, 179(4): 254-260.
[51]	孙斌，姚国敏，段春青，等. 甲状腺相关性眼病眶部⁹⁹Tc^m-生长抑素类似物受体显像与CAS评分的相关性研究[J]. 中国实用眼科杂志，2008, 26(12): 1305-1308.
[52]	Decristoforo C, Mather SJ, Cholewinski W, et al. ^99mTc-EDDA/HYNIC-TOC: a new ^99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with ¹¹¹In-labelled octreotide derivatives[J]. Eur J Nucl Med, 2000, 27(9): 1318-1325.
[53]	杨宝军，李险峰，陆克义，等. ^99mTc-DTPA眼眶显像在甲状腺相关性眼病中的临床应用[J]. 山西医科大学学报，2009, 40(6): 563-566.
[54]	蒋承志，李新辉，赵敏，等. ^99mTc-DTPA眼眶SPECT/CT对甲状腺相关性眼病泪腺炎症的评估价值[J]. 中南大学学报(医学版), 2019, 44(3): 322-328.

Please choose a citation manager

Content to export